In his first one-on-one interview since stepping into the role in April 2024, the former Burberry Americas president shares ...

The tariffs against Canada and Mexico have been postponed a month, but a 10% import tax on China is still on for Tuesday.

Good morning and welcome to Johnson & Johnson's Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.

Yet, when it came to hiring mad scientist Ben Johnson as the Bears’ head coach — one of the best NFL head coaching candidates in recent memory — none of this instability and discord mattered.

Overall, Johnson & Johnson had a strong quarter, continuing to expand its product pipeline and positioning itself well amid market fluctuations. Johnson & Johnson is a diversified healthcare giant ...

Johnson & Johnson (NYSE:JNJ) reported its third-quarter 2024 earnings, surpassing analysts' expectations with an adjusted earnings per share (EPS) of $2.04, slightly above the forecasted $2.02 ...

“We will drill, baby, drill,” the President asserted in his inaugural speech, repeating his shopworn campaign slogan. Whether the oil and gas industry can live up to his grand ambition is an ...

Johnson & Johnson JNJ reported 4.3% top-line growth in 2024, or 7% growth at constant currencies and excluding covid-19 vaccine sales. Assuming the Intra-Cellular ITCI acquisition closes in the ...

More than anyone else, House Speaker Mike Johnson could help get that done. In the roughly 15 months since Johnson was plucked from the backbenches to become the highest-ranking Republican in ...

Alaska may be open to drilling, but that doesn't mean oil and gas companies think it's worth the cost. The Alaska Travel Industry Association advocates for thoughtful discussions on oil and gas ...

Ben Johnson was less than 48 hours removed from the Detroit Lions’ playoff loss to the Washington Commanders when the news broke. The Lions offensive coordinator is finalizing a deal to become ...

Also Read: Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal This approval, granted following FDA Priority Review ...